Connor, Clark & Lunn Investment Management (CC&L)’s Iovance Biotherapeutics IOVA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,770	Closed	-$151K	–	1543
2024 Q2	$151K	Buy	+18,770	New	+$201K	﹤0.01%	1286
2022 Q4	–	Sell	-15,250	Closed	-$146K	–	1318
2022 Q3	$146K	Buy	+15,250	New	+$176K	﹤0.01%	1024
2022 Q1	–	Sell	-10,428	Closed	-$199K	–	1122
2021 Q4	$199K	Sell	10,428 -20,124	-66%	-$443K	﹤0.01%	982
2021 Q3	$753K	Buy	+30,552	New	+$720K	﹤0.01%	693
2016 Q1	–	Sell	-31,200	Closed	-$241K	–	869
2015 Q4	$241K	Sell	31,200 -3,500	-10%	-$24.3K	﹤0.01%	670
2015 Q3	$200K	Buy	+34,700	New	+$270K	﹤0.01%	644

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s IOVA Position: Q3 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 18,770 shares — an estimated $151K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in IOVA in Q3 2015 and held it in 6 quarters. The position peaked at $753K in Q3 2021. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 18,770 Iovance Biotherapeutics shares in Q3 2024, an estimated $151K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Iovance Biotherapeutics in Q3 2015 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Iovance Biotherapeutics position peaked at $753K in Q3 2021.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2024, filed 8 Nov 2024.